Antidepressant News and Research

RSS

Antidepressants are medicines that treat depression. Your doctor can prescribe them for you. They can improve your mood, sleep, appetite and concentration. It may take several weeks for them to help. There are several types of antidepressants. You and your doctor may have to try several before finding what works best for you.

New brain biomarker predicts recovery from treatment-resistant depression

Using a novel deep brain stimulation (DBS) device capable of recording brain signals, researchers have identified a pattern of brain activity or "biomarker" related to clinical signs of recovery from treatment-resistant depression.

20 Sep 2023

Transforming postpartum depression treatment with neurosteroids

A new study in Neuropsychopharmacology delves into the mechanisms of action of brexanolone, the first FDA-approved, rapid-acting antidepressant specifically for postpartum depression (PPD). The research highlights brexanolone's potential anti-inflammatory effects and its impact on GABAA receptors, offering insights into its efficacy and suggesting avenues for further study.

19 Sep 2023

Antidepressants may reduce negative memories, improve memory in depressed individuals

New research from Rice University finds that antidepressants may actually reduce negative memories in individuals suffering from depression while improving overall memory function.

11 Sep 2023

Study finds way to help teen night owls adjust to their natural sleep cycles

Promoting healthy sleep in teen night owls brings adolescents' biology and school demands in alignment.

8 Sep 2023

What are the efficacy and safety of psilocybin in patients with major depressive disorder?

The safety, timing, magnitude, and durability of the antidepressant psilocybin on patients with major depressive disorders.

4 Sep 2023

Adolescence stress exposure impacts rodent brain development and behavior

Adolescence stress exposure in rodents can lead to reduced hippocampal cell proliferation, neuroplasticity, and cognitive impairments, as well as increased depressive-like behaviors. These effects may persist into adulthood but with variable impact.

27 Aug 2023

Genetic reasons behind Raynaud's phenomenon discovered

Researchers at Queen Mary University of London's Precision Healthcare Research Institute (PHURI) and the Berlin Institute of Health (BIH) at Charité – Universitätsmedizin Berlin have identified the genetic causes of Raynaud's phenomenon.

4 Aug 2023

GABA-modulating treatments could help tackle cognitive, affective symptoms associated with depression

Depression is a complex condition correlated with multiple differences in brain function and mechanisms. A new paper spanning known data about the neurotransmitter GABA and its principal receptors showcases evidence of the receptors' importance in depression and potential as therapeutic targets.

3 Aug 2023

Uncommon genetic allele variants may play a vital role in treatment-resistant depression, finds study

The association between treatment-resistant depression and uncommon functional genetic alleles.

3 Aug 2023

Antidepressants may help prevent bipolar depression relapse

Treatment with modern antidepressants may help prevent patients with bipolar disorder from relapsing into a depressive episode, according to an international clinical trial led by researchers at the University of British Columbia.

2 Aug 2023

New drug shows promise for treating chronic neuropathic pain

A non-opioid designer molecule for treating chronic neuropathic pain by calming hyperactive pain-sensing neurons in the peripheral nervous system has had promising results in a preclinical study conducted by researchers at Weill Cornell Medicine and the Burke Neurological Institute.

2 Aug 2023

Study highlights metabolite targets for depression prevention that are easily modifiable through diet interventions

Researchers used a UHPLC and mass spectrometry-based Metabolon platform to identify and characterize circulating metabolites associated with depression.

1 Aug 2023

Trial evaluates purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder

Researchers investigated the safety and pharmacokinetics of JNJ-54175446 in a double-blind, multicenter, randomized controlled trial (RCT).

31 Jul 2023

Doctors urge more research on the use of psilocybin and other psychedelics for women’s cancer distress

It's time to stop prevaricating and explore the use of psilocybin—the active ingredient in 'magic mushrooms'—and other psychedelics to ease the often overwhelming distress faced by women with late stage gynecological cancers, urge doctors in a commentary published online in the International Journal of Gynecological Cancer.

19 Jul 2023

Biomarkers in the brain could redefine mental health conditions

The study of biomarkers in the brain - powered by cutting-edge machine learning techniques - could redefine the way mental health conditions are categorized and diagnosed and lead to more effective, personalized treatments.

10 Jul 2023

Food for thought: South European Atlantic diet shows promising link to lower depression risk

Researchers evaluate the effects of the Southern European Atlantic Diet on depression.

27 Jun 2023

World-renowned researcher receives top award for contributions to clinical psychopharmacology

Dennis Charney, MD, the Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs of the Mount Sinai Health System, has received the prestigious Donald Klein Lifetime Achievement Award from the American Society for Clinical Psychopharmacology (ASCP).

26 Jun 2023

Study links poor sense of smell with increased risk of depression in older adults

In a study that followed more than 2,000 community-dwelling older adults over eight years, researchers at Johns Hopkins Medicine say they have significant new evidence of a link between decreased sense of smell and risk of developing late-life depression.

26 Jun 2023

Antidepressant prescriptions may reduce the risk of testing positive for COVID-19

New research led by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London has found that community mental health patients who were prescribed antidepressants were significantly less likely to test positive for COVID-19 when admitted to inpatient care.

20 Jun 2023

Common laxative prucalopride may be useful as a pro-cognitive treatment in psychiatric conditions

Cognitive deficits accompany mood disorders and other psychiatric conditions, often with debilitating effects.

13 Jun 2023